doxorubicin HCL liposome

Phase 3Small molecule

AAccelerated Community Oncology Research Network

doxorubicin HCL liposome is one of 66 small molecule programs targeting Hand-foot syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hand-Foot SyndromeActive, not recruiting

Ovarian CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Hand-Foot SyndromePhase 3

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

doxorubicin HCL liposome

AAccelerated Community Oncology Research Network

Phase 3

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer2 trials

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Completed·TTelik·Phase 3·NCT00057720·440 enrolled

TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

Completed·TTelik·Phase 3·NCT00102973·244 enrolled

Refractory Solid Tumors1 trial

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019630

Clinical Trial1 trial

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Completed· Sanofi logo

Sanofi·Phase 3·NCT01593228·37 enrolled

Multiple Myeloma1 trial

Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma

Terminated·AAccelerated Community Oncology Research Network·Phase 2·NCT00366106·32 enrolled

Hand-foot syndrome1 trial

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Completed·—·Phase 3·NCT00245050·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for doxorubicin HCL liposome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — doxorubicin HCL liposome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for doxorubicin HCL liposome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Accelerated Community Oncology Research Network company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAccelerated Community Oncology Research Network

doxorubicin HCL liposome

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer2 trials

Refractory Solid Tumors1 trial

Clinical Trial1 trial

Multiple Myeloma1 trial

Hand-foot syndrome1 trial

References

Drug Info

Quick Facts

Related News